{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:17:56Z","timestamp":1787854676406,"version":"build-2784847793"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CAMH Womenmind Fund through the Centre for Addiction and Mental Health Foundation"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec024\">\n                    <jats:title\/>\n                    <jats:p>Antipsychotic medications can cause serious metabolic adverse effects, including type 2 diabetes, with females disproportionally more affected than males. Recently, brain insulin resistance (IR) has been posited as a potential determinant of these effects. Currently there are no direct methods to investigate brain IR, but physiological response to intranasal insulin (INI) can be used as a surrogate marker. INI reliably suppresses endogenous glucose production and modulates resting-state brain activity in humans; however, the current literature has been heavily focused on males. Recently, it has been reported that hormonal fluctuations throughout the menstrual cycle may influence brain insulin sensitivity. Brain insulin sensitivity is greatest in lean females during the follicular phase, matching that of lean males, but decreases during the luteal phase. This study aims to investigate brain insulin action in females across different phases of the menstrual cycle, and to determine how a metabolically high-risk antipsychotic medication, olanzapine, may disrupt these effects. In a single-blind, crossover design, fifteen female participants aged 18\u201335 years will undergo a neuroimaging-based assay of brain insulin action with oral olanzapine (or placebo) and intranasal insulin (or placebo) as pharmacological challenges. All treatment conditions will be administered once in each menstrual phase, meaning that each participant receives every condition twice over the course of the study. Two visits will take place during the follicular phase of the menstrual cycle (i.e., cycle days 3\u201311), and another two visits during the luteal phase (i.e., cycle days 18\u201325). During each study period, participants will receive either oral olanzapine (OLA) or oral placebo (PL) at doses of 5 mg on Day 0 and 10 mg on Day 1. On Day 2, participants will undergo two MRI scans, the first following intranasal placebo (INP) administration and the second following intranasal insulin (INI). It is hypothesized that INI, but not INP, will modulate resting state brain activity during the follicular menstrual cycle phase but not luteal phase. Oral OLA will subsequently inhibit all INI-induced effects, relative to oral PL, during the follicular phase; OLA will have no apparent effect in the luteal phase given pre-existing brain IR. This is the first study to explore the effect of menstrual cycle phases on the anti-insulin action of antipsychotics. This investigation is necessary for the development of suitable treatment options to minimize the metabolic impact of antipsychotics in females.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec001\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Registration:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06251635\" xlink:type=\"simple\">NCT06251635<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0352262","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:24:19Z","timestamp":1787851459000},"page":"e0352262","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of antipsychotics on brain insulin action in females: Study protocol for a placebo-controlled, crossover neuroimaging study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9136-4923","authenticated-orcid":true,"given":"Nicolette","family":"Stogios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret K.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Graff-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9593-5508","authenticated-orcid":true,"given":"Meng-Chuan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2705-5146","authenticated-orcid":true,"given":"Sri Mahavir","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"3","key":"pone.0352262.ref001","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"D Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"issue":"7","key":"pone.0352262.ref002","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2016.16040442","article-title":"Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study","volume":"174","author":"AP Rajkumar","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"6","key":"pone.0352262.ref003","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ahj.2005.02.007","article-title":"Schizophrenia and increased risks of cardiovascular disease","volume":"150","author":"CH Hennekens","year":"2005","journal-title":"Am Heart J"},{"issue":"9","key":"pone.0352262.ref004","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2021.02.858","article-title":"Weight Gain and Metabolic Adverse Effects of Off-Label Second-Generation Antipsychotic Use in the Adult Population: A Systematic Review and Meta-Analysis","volume":"89","author":"N Stogios","year":"2021","journal-title":"Biological Psychiatry"},{"issue":"2","key":"pone.0352262.ref005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"CU Correll","year":"2015","journal-title":"World Psychiatry"},{"issue":"1","key":"pone.0352262.ref006","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1517\/14740338.2015.974549","article-title":"Weight gain and antipsychotics: a drug safety review","volume":"14","author":"R Musil","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"pone.0352262.ref007","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","article-title":"Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study","volume":"71","author":"CU Correll","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"pone.0352262.ref008","article-title":"Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism","volume":"4","author":"LN Castellani","year":"2019","journal-title":"J Psychiatr Brain Sci"},{"issue":"2","key":"pone.0352262.ref009","doi-asserted-by":"crossref","first-page":"8","DOI":"10.64719\/pb.4358","article-title":"Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders","volume":"47","author":"AZ Kraal","year":"2017","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"pone.0352262.ref010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"JP McEvoy","year":"2005","journal-title":"Schizophr Res"},{"issue":"8","key":"pone.0352262.ref011","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1517\/14740338.2014.935761","article-title":"Safety of antipsychotic drugs: focus on therapeutic and adverse effects","volume":"13","author":"F-M Werner","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"pone.0352262.ref012","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1017\/S0033291716003366","article-title":"The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis","volume":"47","author":"E Bora","year":"2017","journal-title":"Psychol Med"},{"issue":"2","key":"pone.0352262.ref013","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2022.3","article-title":"Gender differences in quality of life and the course of schizophrenia: national study","volume":"8","author":"A Rotstein","year":"2022","journal-title":"BJPsych Open"},{"issue":"4","key":"pone.0352262.ref014","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1152\/physrev.00032.2015","article-title":"Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans","volume":"96","author":"S Kullmann","year":"2016","journal-title":"Physiol Rev"},{"key":"pone.0352262.ref015","doi-asserted-by":"crossref","first-page":"107633","DOI":"10.1016\/j.neuropharm.2019.05.010","article-title":"Brain insulin action in schizophrenia: Something borrowed and something new","volume":"163","author":"SM Agarwal","year":"2020","journal-title":"Neuropharmacology"},{"issue":"12","key":"pone.0352262.ref016","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/nm1202-798","article-title":"Hypothalamic insulin signaling is required for inhibition of glucose production","volume":"8","author":"S Obici","year":"2002","journal-title":"Nat Med"},{"issue":"4","key":"pone.0352262.ref017","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.cmet.2012.09.005","article-title":"Insulin activates Erk1\/2 signaling in the dorsal vagal complex to inhibit glucose production","volume":"16","author":"BM Filippi","year":"2012","journal-title":"Cell Metab"},{"issue":"3","key":"pone.0352262.ref018","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2337\/db14-0685","article-title":"Intranasal insulin suppresses endogenous glucose production in humans compared with placebo in the presence of similar venous insulin concentrations","volume":"64","author":"S Dash","year":"2015","journal-title":"Diabetes"},{"issue":"6","key":"pone.0352262.ref019","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1503\/jpn.170092","article-title":"In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact","volume":"42","author":"C Kowalchuk","year":"2017","journal-title":"J Psychiatry Neurosci"},{"issue":"4","key":"pone.0352262.ref020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/hbeh.2000.1588","article-title":"CNS melanocortin system involvement in the regulation of food intake","volume":"37","author":"S Benoit","year":"2000","journal-title":"Horm Behav"},{"issue":"11","key":"pone.0352262.ref021","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.2337\/diabetes.53.11.3024","article-title":"Intranasal insulin reduces body fat in men but not in women","volume":"53","author":"M Hallschmid","year":"2004","journal-title":"Diabetes"},{"issue":"4","key":"pone.0352262.ref022","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2337\/diabetes.55.04.06.db05-1339","article-title":"Gonadal hormones determine sensitivity to central leptin and insulin","volume":"55","author":"DJ Clegg","year":"2006","journal-title":"Diabetes"},{"issue":"1","key":"pone.0352262.ref023","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/s41598-017-01907-w","article-title":"Intranasal insulin enhances brain functional connectivity mediating the relationship between adiposity and subjective feeling of hunger","volume":"7","author":"S Kullmann","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"pone.0352262.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277211","article-title":"Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls","volume":"17","author":"N Stogios","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"pone.0352262.ref025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.npp.1301193","article-title":"Intranasal insulin improves memory in humans: superiority of insulin aspart","volume":"32","author":"C Benedict","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"pone.0352262.ref026","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.ijo.0803722","article-title":"Obese men respond to cognitive but not to catabolic brain insulin signaling","volume":"32","author":"M Hallschmid","year":"2008","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"pone.0352262.ref027","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1210\/jc.2017-01976","article-title":"Dose-Dependent Effects of Intranasal Insulin on Resting-State Brain Activity","volume":"103","author":"S Kullmann","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"pone.0352262.ref028","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.2337\/db14-0477","article-title":"Central insulin administration improves whole-body insulin sensitivity via hypothalamus and parasympathetic outputs in men","volume":"63","author":"M Heni","year":"2014","journal-title":"Diabetes"},{"key":"pone.0352262.ref029","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1159\/000504551","article-title":"Insulin Action in the Hypothalamus Increases Second-Phase Insulin Secretion in Humans","volume":"110","author":"M Heni","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"10","key":"pone.0352262.ref030","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/clinem\/dgab410","article-title":"Central Insulin Modulates Dopamine Signaling in the Human Striatum","volume":"106","author":"S Kullmann","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"pone.0352262.ref031","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1210\/jc.2007-2606","article-title":"Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin","volume":"93","author":"C Benedict","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"pone.0352262.ref032","doi-asserted-by":"crossref","first-page":"782","DOI":"10.2337\/db11-1390","article-title":"Postprandial administration of intranasal insulin intensifies satiety and reduces intake of palatable snacks in women","volume":"61","author":"M Hallschmid","year":"2012","journal-title":"Diabetes"},{"key":"pone.0352262.ref033","article-title":"150-OR: Brain Insulin Sensitivity Is Modulated by Menstrual Cycle","volume":"69","author":"CFC Benkendorff","year":"2020","journal-title":"Diabetes"},{"issue":"12","key":"pone.0352262.ref034","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1210\/jc.2010-0702","article-title":"Longitudinal study of insulin resistance and sex hormones over the menstrual cycle: the BioCycle Study","volume":"95","author":"EH Yeung","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"pone.0352262.ref035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0188-0128(98)00008-6","article-title":"Changes in insulin sensitivity, secretion and glucose effectiveness during menstrual cycle","volume":"30","author":"JM Escalante Pulido","year":"1999","journal-title":"Arch Med Res"},{"issue":"5","key":"pone.0352262.ref036","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/eip.12749","article-title":"Glucose metabolism dysregulation at the onset of mental illness is not limited to first episode psychosis: A systematic review and meta-analysis","volume":"13","author":"S Kucukgoncu","year":"2019","journal-title":"Early Interv Psychiatry"},{"issue":"1","key":"pone.0352262.ref037","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"T Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"pone.0352262.ref038","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/phar.2689","article-title":"The effect of antipsychotic treatment on hormonal, inflammatory, and metabolic biomarkers in healthy volunteers: A systematic review and meta-analysis","volume":"42","author":"KJ Burghardt","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"6","key":"pone.0352262.ref039","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/JCP.0b013e31829e8333","article-title":"Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls","volume":"33","author":"MK Hahn","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"pone.0352262.ref040","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41366-022-01115-1","article-title":"The effect of intranasal insulin on appetite and mood in women with and without obesity: an experimental medicine study","volume":"46","author":"E Schneider","year":"2022","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"pone.0352262.ref041","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000341406","article-title":"Intranasal insulin modulates intrinsic reward and prefrontal circuitry of the human brain in lean women","volume":"97","author":"S Kullmann","year":"2013","journal-title":"Neuroendocrinology"},{"issue":"3","key":"pone.0352262.ref042","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.diabres.2009.03.005","article-title":"Optimal threshold of homeostasis model assessment for insulin resistance in an Iranian population: the implication of metabolic syndrome to detect insulin resistance","volume":"84","author":"A Esteghamati","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"pone.0352262.ref043","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1743-7075-7-26","article-title":"Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007)","volume":"7","author":"A Esteghamati","year":"2010","journal-title":"Nutr Metab (Lond)"},{"issue":"1","key":"pone.0352262.ref044","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0028-3932(71)90067-4","article-title":"The assessment and analysis of handedness: the Edinburgh inventory","volume":"9","author":"RC Oldfield","year":"1971","journal-title":"Neuropsychologia"},{"key":"pone.0352262.ref045","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"DV Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"pone.0352262.ref046","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1037\/1040-3590.8.2.145","article-title":"Revision of the Brief Visuospatial Memory Test: Studies of normal performance, reliability, and validity","volume":"8","author":"RHB Benedict","year":"1996","journal-title":"Psychological Assessment"},{"issue":"5","key":"pone.0352262.ref047","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3758\/BF03203313","article-title":"An automated version of the digit symbol substitution test (DSST)","volume":"14","author":"DR McLeod","year":"1982","journal-title":"Behavior Research Methods & Instrumentation"},{"key":"pone.0352262.ref048","volume-title":"Manual profile of mood states","author":"DM McNair","year":"1971"},{"key":"pone.0352262.ref049","first-page":"133","article-title":"A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables","author":"D Naber","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"pone.0352262.ref050","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0269881103174013","article-title":"The Barnes Akathisia Rating Scale--revisited","volume":"17","author":"TRE Barnes","year":"2003","journal-title":"J Psychopharmacol"},{"issue":"4","key":"pone.0352262.ref051","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1469-8986.1973.tb00801.x","article-title":"Quantification of sleepiness: a new approach","volume":"10","author":"E Hoddes","year":"1973","journal-title":"Psychophysiology"},{"issue":"2","key":"pone.0352262.ref052","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/10601331003777444","article-title":"Blinding assessment in clinical trials: A review of statistical methods and a proposal of blinding assessment protocol","volume":"27","author":"H Bang","year":"2010","journal-title":"Clinical Research and Regulatory Affairs"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:24:26Z","timestamp":1787851466000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352262"}},"subtitle":[],"editor":[{"given":"Hirofumi","family":"Hirakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":52,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0352262","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}